

Kun-Huei Yeh

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5892050/kun-huei-yeh-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

159
papers

6,974
citations

32
h-index

82
g-index

166
ext. papers

8,278
ext. citations

4.8
avg. IF

5.1
L-index

#	Paper	IF	Citations
159	A randomized, double-blind, phase III study comparing trifluridine/tipiracil hydrochloride therapy versus placebo in resected colorectal cancer patients who are positive for blood circulating tumor DNA after standard adjuvant therapy (EPOC 1905): ALTAIR trial in CIRCULATE-Japan (trial in <i>Journal of Clinical Oncology</i> , 2022 , 40, TPS315-TPS317)	2.2	0
158	A single-arm phase II study of cabozantinib and atezolizumab in patients with recurrent or metastatic esophageal squamous cell carcinoma (R/M ESCC) who failed platinum-based chemotherapy.. <i>Journal of Clinical Oncology</i> , 2022 , 40, TPS364-TPS364	2.2	
157	Trastuzumab deruxtecan in patients with HER2-overexpressing locally advanced, unresectable, or metastatic colorectal cancer (mCRC): A randomized, multicenter, phase 2 study (DESTINY-CRC02).. <i>Journal of Clinical Oncology</i> , 2022 , 40, TPS224-TPS224	2.2	0
156	A pilot study of metabolomic pathways associated with fatigue in patients with colorectal cancer receiving chemotherapy.. <i>European Journal of Oncology Nursing</i> , 2022 , 56, 102096	2.8	0
155	Proteasome inhibitors restore the STAT1 pathway and enhance the expression of MHC class I on human colon cancer cells. <i>Journal of Biomedical Science</i> , 2021 , 28, 75	13.3	2
154	Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab. <i>Gastric Cancer</i> , 2021 , 24, 946-958	7.6	13
153	Chemotherapy agents stimulate dendritic cells against human colon cancer cells through upregulation of the transporter associated with antigen processing. <i>Scientific Reports</i> , 2021 , 11, 9080	4.9	1
152	Association between risk factors, molecular features and CpG island methylator phenotype colorectal cancer among different age groups in a Taiwanese cohort. <i>British Journal of Cancer</i> , 2021 , 125, 48-54	8.7	
151	A Pilot Study of Metabolomic Pathways Associated With Fatigue in Survivors of Colorectal Cancer. <i>Biological Research for Nursing</i> , 2021 , 23, 42-49	2.6	3
150	Comparison of clinicopathological features and treatment outcomes in aggressive primary intestinal B- and T/NK-cell lymphomas. <i>Journal of the Formosan Medical Association</i> , 2021 , 120, 293-302	3.2	3
149	Negative prognostic implications of splenomegaly in nivolumab-treated advanced or recurrent pancreatic adenocarcinoma. <i>Oncolmmunology</i> , 2021 , 10, 1973710	7.2	1
148	Real-world evidence of the safety and effectiveness of regorafenib in Taiwanese patients with metastatic colorectal cancer: CORRELATE Taiwan. <i>Journal of the Formosan Medical Association</i> , 2021 , 120, 2023-2031	3.2	2
147	Spectrum of cancer patients receiving renal biopsy. <i>Journal of the Formosan Medical Association</i> , 2021 , 121, 152-152	3.2	
146	Contribution of nuclear BCL10 expression to tumor progression and poor prognosis of advanced and/or metastatic pancreatic ductal adenocarcinoma by activating NF- κ B-related signaling. <i>Cancer Cell International</i> , 2021 , 21, 436	6.4	0
145	Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study. <i>Gastric Cancer</i> , 2021 , 1	7.6	3
144	Complement C1q mediates the expansion of periportal hepatic progenitor cells in senescence-associated inflammatory liver. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 6717-6725	11.5	4
143	Pembrolizumab (pembro) versus standard of care chemotherapy (chemo) in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4523-4523	2.2	5

142	A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data. <i>Gastric Cancer</i> , 2020 , 23, 510-519	7.6	72
141	Regorafenib in Chinese patients with metastatic colorectal cancer: Subgroup analysis of the phase 3 CONCUR trial. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020 , 35, 1307-1316	4	4
140	A multicenter prospective study of first-line antibiotic therapy for early-stage gastric mucosa-associated lymphoid tissue lymphoma and diffuse large B-cell lymphoma with histological evidence of mucosa-associated lymphoid tissue. <i>Haematologica</i> , 2020 , 105, e349-e354	6.6	1
139	Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer. <i>Gastric Cancer</i> , 2020 , 23, 143-153	7.6	26
138	Low-dose nab-paclitaxel-based combination chemotherapy in heavily pretreated pancreatic cancer patients. <i>Journal of the Formosan Medical Association</i> , 2020 , 119, 97-105	3.2	1
137	A nationwide survey of fatigue in cancer patients in Taiwan: an unmet need. <i>Japanese Journal of Clinical Oncology</i> , 2020 , 50, 693-700	2.8	4
136	Novel Insights of Lymphomagenesis of -Dependent Gastric Mucosa-Associated Lymphoid Tissue Lymphoma. <i>Cancers</i> , 2019 , 11,	6.6	17
135	MORPHEUS: A phase Ib/II study platform evaluating the safety and clinical efficacy of cancer immunotherapy (CIT)Based combinations in gastrointestinal (GI) cancers.. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS467-TPS467	2.2	7
134	CpG Island Methylator Phenotype May Predict Poor Overall Survival of Patients with Stage IV Colorectal Cancer. <i>Oncology</i> , 2019 , 96, 156-163	3.6	4
133	Phase II study of metabolic response to one-cycle chemotherapy in patients with locally advanced esophageal squamous cell carcinoma. <i>Journal of the Formosan Medical Association</i> , 2019 , 118, 1024-1030 ^{3,2}	3.2	3
132	A Phase I Study of S-1-based Concurrent Chemoradiotherapy Followed by Gemcitabine and S-1 in Metastatic Pancreatic Adenocarcinoma. <i>Anticancer Research</i> , 2018 , 38, 4805-4812	2.3	3
131	Aflibercept plus FOLFIRI in Asian patients with pretreated metastatic colorectal cancer: a randomized Phase III study. <i>Future Oncology</i> , 2018 , 14, 2031-2044	3.6	11
130	Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. <i>Lancet, The</i> , 2018 , 392, 123-133	40	624
129	The prognostic role of CpG island methylator phenotype in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 667-667	2.2	1
128	Number of Resected Lymph Nodes and Survival of Patients with Locally Advanced Esophageal Squamous Cell Carcinoma Receiving Preoperative Chemoradiotherapy. <i>Anticancer Research</i> , 2018 , 38, 1569-1577	2.3	7
127	Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. <i>Journal of Clinical Oncology</i> , 2018 , 36, 276-282	2.2	357
126	Durable response to programmed death-1 (PD-1) blockade in a metastatic gastric cancer patient with mismatch repair deficiency and microsatellite instability. <i>Journal of Cancer Research and Practice</i> , 2017 , 4, 72-75	0.4	
125	Expressions of the CagA protein and CagA-signaling molecules predict Helicobacter pylori dependence of early-stage gastric DLBCL. <i>Blood</i> , 2017 , 129, 188-198	2.2	13

124	First-line antibiotic therapy in <i>Helicobacter pylori</i> -negative low-grade gastric mucosa-associated lymphoid tissue lymphoma. <i>Scientific Reports</i> , 2017 , 7, 14333	4.9	13
123	Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2017 , 390, 2461-2471	4.0	1123
122	The B-cell-activating factor signalling pathway is associated with <i>Helicobacter pylori</i> independence in gastric mucosa-associated lymphoid tissue lymphoma without t(11;18)(q21;q21). <i>Journal of Pathology</i> , 2017 , 241, 420-433	9.4	9
121	Do-not-resuscitate consent signed by patients indicates a more favorable quality of end-of-life care for patients with advanced cancer. <i>Supportive Care in Cancer</i> , 2017 , 25, 533-539	3.9	7
120	Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study. <i>Clinical Colorectal Cancer</i> , 2017 , 16, e73-e88	3.8	10
119	Real-world dosing of regorafenib in metastatic colorectal cancer (mCRC): Interim analysis from the prospective, observational CORRELATE study. <i>Annals of Oncology</i> , 2017 , 28, iii10	10.3	6
118	Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review. <i>Cancer Research and Treatment</i> , 2017 , 49, 851-868	5.2	41
117	Impact of tumor location on outcomes in patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG): An interim analysis from the prospective, observational CORRELATE study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3567-3567	2.2	3
116	Safety and effectiveness of regorafenib (REG) in patients with metastatic colorectal cancer (mCRC) in routine clinical practice: An interim analysis (IA) from the prospective, observational CORRELATE study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 700-700	2.2	4
115	Distinct Clinicopathological Features and Prognosis of <i>Helicobacter pylori</i> Negative Gastric Cancer. <i>PLoS ONE</i> , 2017 , 12, e0170942	3.7	15
114	Association of MDM2 expression with shorter progression-free survival and overall survival in patients with advanced pancreatic cancer treated with gemcitabine-based chemotherapy. <i>PLoS ONE</i> , 2017 , 12, e0180628	3.7	3
113	Irinotecan and Oxaliplatin Might Provide Equal Benefit as Adjuvant Chemotherapy for Patients with Resectable Synchronous Colon Cancer and Liver-confined Metastases: A Nationwide Database Study. <i>Anticancer Research</i> , 2017 , 37, 7095-7104	2.3	4
112	Computed tomographic characteristics for patients with unresectable gastric cancer harboring low-volume peritoneal carcinomatosis. <i>Medical Oncology</i> , 2017 , 34, 143	3.7	1
111	Comparison of irinotecan and oxaliplatin as adjuvant chemotherapy for patients with resectable synchronous colon cancer plus liver-confined metastases: A retrospective nationwide database study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 624-624	2.2	
110	A phase II study of early FDG-PET evaluation after one-cycle chemotherapy in patients with locally advanced esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy: Final report.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4042-4042	2.2	
109	Case report: mismatch repair proficiency and microsatellite stability in gastric cancer may not predict programmed death-1 blockade resistance. <i>Journal of Hematology and Oncology</i> , 2016 , 9, 29	22.4	17
108	Frequent BRAF mutation in early-onset colorectal cancer in Taiwan: association with distinct clinicopathological and molecular features and poor clinical outcome. <i>Journal of Clinical Pathology</i> , 2016 , 69, 319-25	3.9	3
107	Results of Phase II trial of AUY922, a novel heat shock protein inhibitor in patients with metastatic gastrointestinal stromal tumor (GIST) and imatinib and sunitinib therapy.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 134-134	2.2	6

106	A phase 2 study of BGJ398 in patients (pts) with advanced or metastatic FGFR-altered cholangiocarcinoma (CCA) who failed or are intolerant to platinum-based chemotherapy.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 335-335	2.2	37
105	Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer. <i>World Journal of Gastroenterology</i> , 2016 , 22, 7275-88	5.6	21
104	The recurrence patterns and post-recurrence survivals in patients with locally advanced esophageal squamous cell carcinoma (ESCC) treated with preoperative paclitaxel/cisplatin-based chemoradiotherapy.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 80-80	2.2	
103	Low-dose nab-paclitaxel-based combination chemotherapy in heavily-pretreated pancreatic or ampullary cancer patients: Taiwanese single-center case series.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e15695-e15695	2.2	
102	Association of the number of dissected lymph node (LN) with the survivals of locally advanced esophageal squamous cell carcinoma (ESCC) patients received preoperative chemoradiotherapy (CRT) followed by surgery.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e15543-e15543	2.2	
101	Efficacy of frontline antibiotics therapy in the treatment of Helicobacter pylori-negative gastric low-grade mucosa-associated lymphoid tissue lymphoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e19024 ^{2,2} -e19024	2.2	
100	Association of radiotherapy with favorable prognosis in daily clinical practice for treatment of locally advanced and metastatic pancreatic cancer. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016 , 31, 2004-2012	4	5
99	BRAF mutation may have different prognostic implications in early- and late-stage colorectal cancer. <i>Medical Oncology</i> , 2016 , 33, 39	3.7	18
98	Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: a nationwide cohort study. <i>BMC Cancer</i> , 2016 , 16, 327	4.8	32
97	Hypoxia-activated cytotoxic agent tirapazamine enhances hepatic artery ligation-induced killing of liver tumor in HBx transgenic mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, 11937-11942	11.5	22
96	Statin Use Is Associated With Improved Prognosis of Colorectal Cancer in Taiwan. <i>Clinical Colorectal Cancer</i> , 2015 , 14, 177-184.e4	3.8	27
95	Young patients with colorectal cancer have increased risk of second primary cancers. <i>Japanese Journal of Clinical Oncology</i> , 2015 , 45, 1029-35	2.8	8
94	Elevated p53 promotes the processing of miR-18a to decrease estrogen receptor- β in female hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2015 , 136, 761-70	7.5	30
93	Helicobacter pylori CagA Translocation Is Closely Associated With the Expression of CagA-signaling Molecules in Low-grade Gastric Mucosa-associated Lymphoid Tissue Lymphoma. <i>American Journal of Surgical Pathology</i> , 2015 , 39, 761-6	6.7	13
92	Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2015 , 16, 619-29	21.7	428
91	Gemcitabine plus cisplatin for patients with recurrent or metastatic nasopharyngeal carcinoma in Taiwan: a multicenter prospective Phase II trial. <i>Japanese Journal of Clinical Oncology</i> , 2015 , 45, 819-27	2.8	15
90	Postchemoradiotherapy Pathologic Stage Classified by the American Joint Committee on the Cancer Staging System Predicts Prognosis of Patients with Locally Advanced Esophageal Squamous Cell Carcinoma. <i>Journal of Thoracic Oncology</i> , 2015 , 10, 1481-9	8.9	8
89	Heterogeneous cell origin of Helicobacter pylori-dependent high-grade gastric lymphomas.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e19520-e19520	2.2	0

88	Effects of regorafenib therapy on health-related quality of life (HRQoL) in patients with metastatic colorectal cancer (mCRC) in the phase III CONCUR trial.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 697-697	2.2	1
87	Postchemoradiotherapy (CRT) pathologic stage classified by American Joint Committee on Cancer (AJCC) staging system to predict prognosis of patients with locally advanced esophageal squamous cell carcinoma (ESCC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 158-158	2.2	
86	Final analysis of the phase 2 APEC study: Overall survival (OS) data and biomarker subanalyses for first-line FOLFOX or FOLFIRI with cetuximab (cet) once every 2 weeks in patients (pts) with KRAS or RAS (KRAS and NRAS, exons 2-4) wild-type (wt) metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 566-566	2.2	
85	Primary tumor site as a useful predictor for cetuximab efficacy in KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e14592-e14592	2.2	
84	Cetuximab Might Be Detrimental to Metastatic Colorectal Cancer Patients with KRAS Codon 12 Mutations. <i>Anticancer Research</i> , 2015 , 35, 4207-14	2.3	2
83	A multicenter phase II study of biweekly capecitabine in combination with oxaliplatin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2014 , 73, 799-806	3.5	10
82	Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2039-49	2.2	407
81	Phase II multicentered study of low-dose everolimus plus cisplatin and weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin as first-line treatment for patients with advanced gastric cancer. <i>Oncology</i> , 2014 , 87, 104-13	3.6	23
80	Type 2 diabetes mellitus is associated with increased mortality in Chinese patients receiving curative surgery for colon cancer. <i>Oncologist</i> , 2014 , 19, 951-8	5.7	19
79	Beware imposters: MA-1, a novel MALT lymphoma cell line, is misidentified and corresponds to Pfeiffer, a diffuse large B-cell lymphoma cell line-A reply: despite the same 8-code STR, MA-1 and Pfeiffer are cytogenetically diverse. <i>Genes Chromosomes and Cancer</i> , 2014 , 53, 211-3	5	3
78	Unmet supportive care needs of patients with colorectal cancer: significant differences by type D personality. <i>Oncology Nursing Forum</i> , 2014 , 41, E3-11	1.7	17
77	Chlorhexidine for the prevention of bloodstream infection associated with totally implantable venous ports in patients with solid cancers. <i>Supportive Care in Cancer</i> , 2014 , 22, 1189-97	3.9	11
76	Oxaliplatin-based chemotherapy is more beneficial in KRAS mutant than in KRAS wild-type metastatic colorectal cancer patients. <i>PLoS ONE</i> , 2014 , 9, e86789	3.7	14
75	Risk of second primary malignancies in young patients with colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e14533-e14533	2.2	
74	Association of helicobacter pylori CagA translocation with the expression of CagA-signaling transduction molecules in gastric mucosa-associated lymphoid tissue lymphoma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8571-8571	2.2	
73	Molecular-targeted therapy for chemotherapy-refractory gastric cancer: a case report and literature review. <i>Anticancer Research</i> , 2014 , 34, 3695-9	2.3	6
72	Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3935-43	2.2	358
71	Management of gastric cancer in Asia: resource-stratified guidelines. <i>Lancet Oncology</i> , 2013 , 14, e535-47	21.7	344

70	Telomerase-specific oncolytic adenoviral therapy for orthotopic hepatocellular carcinoma in HBx transgenic mice. <i>International Journal of Cancer</i> , 2013 , 132, 1451-62	7.5	19
69	Oxaliplatin-based Chemotherapy Might Provide Longer Progression-Free Survival in KRAS Mutant Metastatic Colorectal Cancer. <i>Translational Oncology</i> , 2013 , 6, 363-9	4.9	7
68	Predictors of bloodstream infection associated with permanently implantable venous port in solid cancer patients. <i>Annals of Oncology</i> , 2013 , 24, 463-468	10.3	27
67	No evidence of IGH-MALT1-translocation in the Ma-1 cell line--a reply. <i>Genes Chromosomes and Cancer</i> , 2013 , 52, 593-4	5	1
66	Regular statin users and colorectal cancer (CRC) prognosis.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3554-3554	2.2	1
65	Concurrent chemoradiotherapy with cetuximab plus twice-weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal squamous cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4099-4099	2.2	1
64	ADAR2-mediated editing of miR-214 and miR-122 precursor and antisense RNA transcripts in liver cancers. <i>PLoS ONE</i> , 2013 , 8, e81922	3.7	26
63	Association of diabetes mellitus with increased mortality in patients receiving curative surgery for colon cancer.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 399-399	2.2	2
62	Prevalence of gene amplifications of SOX-2, c-MET, and FGFR1 in Asian patients with esophageal squamous cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e15127-e15127	2.2	
61	Clinicopathologic features and treatment outcome of primary intestinal non-Hodgkin lymphoma: A single center experience.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e19523-e19523	2.2	
60	Effective treatment of aggressive B-cell lymphomas by downregulated NIK-induced noncanonical NF- κ B pathway activation through inhibition of BAFF.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e13554-e13554	2.2	2
59	Efficacy and safety of every-2-weeks cetuximab combined with FOLFOX or FOLFIRI as first-line therapy in patients with KRAS wild-type metastatic colorectal cancer (mCRC): An Asia-Pacific nonrandomized phase II study (APEC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, e14501-e14501	2.2	
58	Helicobacter pylori eradication therapy is effective in the treatment of early-stage H pylori-positive gastric diffuse large B-cell lymphomas. <i>Blood</i> , 2012 , 119, 4838-44; quiz 5057	2.2	101
57	Estrogen receptor β represses transcription of HBV genes via interaction with hepatocyte nuclear factor 4 β . <i>Gastroenterology</i> , 2012 , 142, 989-998.e4	13.3	85
56	KRAS mutation is a predictor of oxaliplatin sensitivity in colon cancer cells. <i>PLoS ONE</i> , 2012 , 7, e50701	3.7	30
55	Geographic difference in safety and efficacy of systemic chemotherapy for advanced gastric or gastroesophageal carcinoma: a meta-analysis and meta-regression. <i>Gastric Cancer</i> , 2012 , 15, 265-280	7.6	15
54	Geographic difference in safety and efficacy of systemic chemotherapy for advanced gastric or gastroesophageal carcinoma: a meta-analysis and meta-regression. <i>Gastric Cancer</i> , 2012 , 15, 265-80	7.6	14
53	Safety of everolimus (EVE) in Asian patients (pts) with advanced gastric cancer (AGC) enrolled in the phase III GRANITE-1 study.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4081-4081	2.2	

52	Lack of compensatory pAKT activation and eIF4E phosphorylation of lymphoma cells towards mTOR inhibitor, RAD001. <i>European Journal of Cancer</i> , 2011 , 47, 1244-57	7.5	16
51	Recent advances in the treatment of metastatic colorectal cancer in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2011 , 110, 1-3	3.2	1
50	Phase I, pharmacokinetic, and bone marrow drug-level studies of tri-monthly 48-h infusion of high-dose 5-fluorouracil and leucovorin in patients with metastatic colorectal cancers. <i>Anti-Cancer Drugs</i> , 2011 , 22, 290-8	2.4	3
49	A phase II and pharmacokinetic study of first line S-1 for advanced gastric cancer in Taiwan. <i>Cancer Chemotherapy and Pharmacology</i> , 2011 , 67, 1281-9	3.5	4
48	t(11;18)(q21;q21) translocation as predictive marker for non-responsiveness to salvage thalidomide therapy in patients with marginal zone B-cell lymphoma with gastric involvement. <i>Cancer Chemotherapy and Pharmacology</i> , 2011 , 68, 1387-95	3.5	11
47	Establishment of a novel MALT lymphoma cell line, ma-1, from a patient with t(14;18)(q32;q21)-positive Helicobacter pylori-independent gastric MALT lymphoma. <i>Genes Chromosomes and Cancer</i> , 2011 , 50, 908-21	5	7
46	Depletion of Eatenin from mature hepatocytes of mice promotes expansion of hepatic progenitor cells and tumor development. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011 , 108, 18384-9	11.5	31
45	Personality trait and quality of life in colorectal cancer survivors. <i>Oncology Nursing Forum</i> , 2011 , 38, E221-8	4.8	13
44	EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment. <i>Lung Cancer</i> , 2009 , 64, 346-51	5.9	40
43	Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells. <i>Cancer Research</i> , 2008 , 68, 6698-707	10.1	105
42	Overexpression of B cell-activating factor of TNF family (BAFF) is associated with Helicobacter pylori-independent growth of gastric diffuse large B-cell lymphoma with histologic evidence of MALT lymphoma. <i>Blood</i> , 2008 , 112, 2927-34	2.2	43
41	Long-term follow-up of gastrectomized patients with mucosa-associated lymphoid tissue lymphoma: need for a revisit of surgical treatment. <i>Annals of Surgery</i> , 2008 , 247, 265-9	7.8	15
40	Minimal Toxicity to Myeloid Progenitor Cells of Weekly 24-Hr Infusion of High-Dose 5-Fluorouracil: Direct Evidence from Colony Forming Unit-Granulocyte and Monocyte (CFU-GM) Clonogenic Assay. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2008 , 86, 122-124		
39	Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma. <i>Anti-Cancer Drugs</i> , 2007 , 18, 703-8	2.4	7
38	A pathway for tumor necrosis factor-alpha-induced Bcl10 nuclear translocation. Bcl10 is up-regulated by NF-kappaB and phosphorylated by Akt1 and then complexes with Bcl3 to enter the nucleus. <i>Journal of Biological Chemistry</i> , 2006 , 281, 167-75	5.4	36
37	Disseminated Mycobacterium kansasii infection in an HIV-negative patient presenting with mimicking multiple bone metastases. <i>Diagnostic Microbiology and Infectious Disease</i> , 2006 , 54, 211-6	2.9	8
36	Survival outcome of inoperable non-small cell lung cancer patients receiving conventional dose epirubicin and Paclitaxel as first-line treatment. <i>Oncology</i> , 2005 , 68, 350-5	3.6	4
35	Phase II study of weekly paclitaxel and 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of recurrent or metastatic gastric cancer. <i>Oncology</i> , 2005 , 69, 88-95	3.6	17

34	Somatic mutations in epidermal growth factor receptor underlying complete responsiveness to gefitinib in a Taiwanese female patient with metastatic adenocarcinoma of lung. <i>Anti-Cancer Drugs</i> , 2005 , 16, 739-42	2.4	2
33	Nuclear expression of BCL10 or nuclear factor kappa B helps predict Helicobacter pylori-independent status of low-grade gastric mucosa-associated lymphoid tissue lymphomas with or without t(11;18)(q21;q21). <i>Blood</i> , 2005 , 106, 1037-41	2.2	62
32	Expression of CD86 and increased infiltration of NK cells are associated with Helicobacter pylori-dependent state of early stage high-grade gastric MALT lymphoma. <i>World Journal of Gastroenterology</i> , 2005 , 11, 4357-62	5.6	13
31	Nuclear expression of BCL10 or nuclear factor kappa B predicts Helicobacter pylori-independent status of early-stage, high-grade gastric mucosa-associated lymphoid tissue lymphomas. <i>Journal of Clinical Oncology</i> , 2004 , 22, 3491-7	2.2	53
30	Suppression of MEK/ERK signaling pathway enhances cisplatin-induced NF-kappaB activation by protein phosphatase 4-mediated NF-kappaB p65 Thr dephosphorylation. <i>Journal of Biological Chemistry</i> , 2004 , 279, 26143-8	5.4	88
29	Phosphorylation of p53 on Thr55 by ERK2 is necessary for doxorubicin-induced p53 activation and cell death. <i>Oncogene</i> , 2004 , 23, 3580-8	9.2	61
28	Down-regulation of thymidylate synthase expression and its steady-state mRNA by oxaliplatin in colon cancer cells. <i>Anti-Cancer Drugs</i> , 2004 , 15, 371-6	2.4	30
27	Recent advances in therapy for gastric cancer. <i>Journal of the Formosan Medical Association</i> , 2004 , 103, 171-85	3.2	5
26	Involvement of nuclear transcription factor-kappa B in low-dose doxorubicin-induced drug resistance of cervical carcinoma cells. <i>Biochemical Pharmacology</i> , 2003 , 66, 25-33	6	34
25	High-dose tamoxifen modulates drug resistance to doxorubicin, dacarbazine and ifosfamide in metastatic uterine leiomyosarcoma. <i>Anticancer Research</i> , 2003 , 23, 5133-7	2.3	2
24	Increase of the resistance of human cervical carcinoma cells to cisplatin by inhibition of the MEK to ERK signaling pathway partly via enhancement of anticancer drug-induced NF kappa B activation. <i>Biochemical Pharmacology</i> , 2002 , 63, 1423-30	6	113
23	High-frequency microsatellite instability predicts better chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV sporadic colorectal cancer after palliative bowel resection. <i>International Journal of Cancer</i> , 2002 , 101, 519-25	7.5	97
22	P53 overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection. <i>International Journal of Cancer</i> , 2002 , 97, 451-7	7.5	56
21	A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil. <i>Journal of Clinical Oncology</i> , 2002 , 20, 2041-7	2.3	7
20	The F-box protein SKP2 binds to the phosphorylated threonine 380 in cyclin E and regulates ubiquitin-dependent degradation of cyclin E. <i>Biochemical and Biophysical Research Communications</i> , 2001 , 281, 884-90	3.4	48
19	Nuclear extracellular signal-regulated kinase 2 phosphorylates p53 at Thr55 in response to doxorubicin. <i>Biochemical and Biophysical Research Communications</i> , 2001 , 284, 880-6	3.4	32
18	Minimal toxicity to myeloid progenitor cells of weekly 24-hr infusion of high-dose 5-fluorouracil: direct evidence from colony forming unit-granulocyte and monocyte (CFU-GM) clonogenic assay. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2000 , 86, 122-4		9
17	p27(Kip1) ubiquitination and degradation is regulated by the SCF(Skp2) complex through phosphorylated Thr187 in p27. <i>Current Biology</i> , 1999 , 9, 661-4	6.3	783

16	High dose tamoxifen plus cisplatin and etoposide in the treatment of patients with advanced, inoperable nonsmall cell lung carcinoma. <i>Cancer</i> , 1999 , 86, 415-20	6.4	10
15	Quiescent nasal T/NK cell lymphoma manifested as primary central nervous system lymphoma. <i>American Journal of Hematology</i> , 1999 , 60, 161-3	7.1	28
14	High-dose therapy with peripheral blood stem cell (PBSC) support using an innovative mobilization regimen in patients with high-risk primary or chemoresponsive metastatic breast cancers. <i>Breast Cancer Research and Treatment</i> , 1998 , 49, 237-44	4.4	2
13	5-Fluorouracil-related encephalopathy: at least two distinct pathogenetic mechanisms exist - reply. <i>British Journal of Cancer</i> , 1998 , 77, 1711-1712	8.7	3
12	High expression of thymidylate synthase is associated with the drug resistance of gastric carcinoma to high dose 5-fluorouracil-based systemic chemotherapy. <i>Cancer</i> , 1998 , 82, 1626-31	6.4	80
11	Systemic chemotherapy alone for patients with non-acquired immunodeficiency syndrome-related central nervous system lymphoma: a pilot study of the BOMES protocol. <i>Cancer</i> , 1998 , 82, 1946-51	6.4	45
10	Gastric cancer associated with acute disseminated intravascular coagulation: successful initial treatment with weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin. <i>British Journal of Haematology</i> , 1998 , 100, 769-72	4.5	24
9	T-cell malignant lymphoma with conjunctival involvement. <i>American Journal of Ophthalmology</i> , 1998 , 125, 717-9	4.9	11
8	Inhibition of the membrane translocation and activation of protein kinase C, and potentiation of doxorubicin-induced apoptosis of hepatocellular carcinoma cells by tamoxifen. <i>Biochemical Pharmacology</i> , 1998 , 55, 523-31	6	51
7	Relatively low expression of multidrug resistance-1 (MDR-1) and its possible clinical implication in gastric cancers. <i>Journal of Clinical Gastroenterology</i> , 1998 , 26, 274-8	3	10
6	Weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of advanced gastric cancers. An effective and low-toxic regimen for patients with poor general condition. <i>Oncology</i> , 1997 , 54, 275-80	3.6	54
5	Chronic oral etoposide and tamoxifen in the treatment of far-advanced hepatocellular carcinoma 1996 , 77, 872-877		23
4	Long-term disease-free survival after autologous bone marrow transplantation in a primary plasma cell leukaemia: detection of minimal residual disease in the transplant marrow by third-complementarity-determining region-specific probes. <i>British Journal of Haematology</i> , 1995 , 89, 914-6	4.5	7
3	Primary T cell leptomenigeal lymphoma--successful treatment with systemic chemotherapy. <i>Oncology</i> , 1995 , 52, 501-4	3.6	10
2	Panhypopituitarism caused by solitary parasellar metastasis from lung cancer. <i>Chest</i> , 1994 , 105, 951-3	5.3	16
1	Fibrosing cholestatic hepatitis in a hepatitis B surface antigen carrier after renal transplantation. <i>Gastroenterology</i> , 1994 , 107, 1514-8	13.3	79